生血宝合剂联合重组人促红细胞生成素治疗多发性骨髓瘤并发贫血临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R733.3;R556.9

基金项目:


Clinical Study on Shengxuebao Mixture Combined with Recombinant Human Erythro⁃ poietin for Multiple Myeloma Complicated with Anemia
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察生血宝合剂联合重组人促红细胞生成素(rhEPO) 治疗多发性骨髓瘤并发贫血的临床 疗效。方法:选取88 例多发性骨髓瘤并发贫血患者,按随机数字表法分为观察组和对照组各44 例。2 组均给 予常规治疗与护理干预,对照组在此基础上给予皮下注射rhEPO 治疗,观察组在对照组基础上联合生血宝合 剂治疗,2 组均治疗8 周。比较2 组临床疗效,治疗前后中医证候评分、血常规指标[血红蛋白(Hb)、网织 红细胞计数百分比(RET%)、红细胞计数(RBC)、白细胞计数(WBC)、血小板计数(BPC)],以及治疗期 间不良反应发生率。结果:治疗后,观察组临床疗效总有效率93.18%,高于对照组81.82%,差异有统计学意 义(P<0.05)。2 组面色无华、头晕耳鸣、腰膝酸软、心悸气短评分均较治疗前降低(P<0.05),观察组面色 无华、头晕耳鸣、腰膝酸软、心悸气短评分均低于对照组(P<0.05)。2 组Hb、RET%、RBC、WBC、BPC 水 平均较治疗前升高(P<0.05),观察组Hb、RET%、RBC、WBC、BPC 水平均高于对照组(P<0.05)。观察组 不良反应发生率15.91%,与对照组11.36%比较,差异无统计学意义(P>0.05)。结论:生血宝合剂联合 rhEPO 治疗多发性骨髓瘤并发贫血疗效确切,能显著改善临床症状、血常规指标,安全性良好。

    Abstract:

    Abstract: Objective: To observe the clinical effect of Shengxuebao Mixture combined with recombinant human erythropoietin (rhEPO) for multiple myeloma complicated with anemia. Methods: A total of 88 cases of patients with multiple myeloma complicated with anemia were selected and divided into the observation group and the control group according to the random number table method,with 44 cases in each group. Both groups were given conventional treatment and nursing intervention;the control group was additionally treated with hypodermic injection of rhEPO, and the observation group was additionally treated with Shengxuebao Mixture based on the treatment of the control group. Both groups were treated for 8 weeks. Traditional Chinese medicine (TCM) syndrome scores,blood routine indexes [hemoglobin (Hb), reticulocyte (RET%),red blood cell count (RBC),white blood cell count (WBC),and blood platelet count (BPC)] before and after treatment,clinical effects,and the incidence of adverse reactions during treatment were compared between the two groups. Results: After treatment, the total clinical effective rate was 93.18% in the observation group,higher than that of 81.82% in the control group (P<0.05). The scores of white complexion, dizziness and tinnitus, soreness and weakness in the lumbar and knee, and palpitations and shortness of breath in the two groups were decreased when compared with those before treatment (P<0.05),and the scores of white complexion,dizziness and tinnitus,soreness and weakness in the lumbar and knee,and palpitations and shortness of breath in the observation group were lower than those in the control group (P<0.05). The levels of Hb,RET%,RBC,WBC,and BPC in the two groups were increased when compared with those before treatment (P<0.05), and the levels of Hb, RET% , RBC,WBC,and BPC in the observation group were higher than those in the control group (P<0.05). The incidence of adverse reactions was 15.91% in the observation group and 11.36% in the control group, there being no significance in the difference (P>0.05). Conclusion:Shengxuebao Mixture combined with rhEPO has a definite curative effect in the treatment of multiple myeloma complicated with anemia and can effectively alleviate clinical symptoms and improve anemia state,with good safety.

    参考文献
    相似文献
    引证文献
引用本文

杨丽超,方文娟,张芬娟,张仓健.生血宝合剂联合重组人促红细胞生成素治疗多发性骨髓瘤并发贫血临床研究[J].新中医,2023,55(18):102-106

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2023-09-22
  • 出版日期:
文章二维码